Navigating the Preclinical "Valley of Death": The Role of AI in Comprehensive Property Optimization
The transition from identifying a promising drug candidate to initiating human clinical trials is often described as the "valley of death" in pharmaceutical R&D. During this phase, structural brilliance alone isn’t enough; a molecule must possess the right "drug-like" properties to survive. Historically, failure rates at this stage have been high due to poor metabolic profiles or...
0 Commentarii 0 Distribuiri 23 Views 0 previzualizare